Ignacio Melero

50.4k total citations · 20 hit papers
396 papers, 28.2k citations indexed

About

Ignacio Melero is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ignacio Melero has authored 396 papers receiving a total of 28.2k indexed citations (citations by other indexed papers that have themselves been cited), including 262 papers in Oncology, 255 papers in Immunology and 58 papers in Molecular Biology. Recurrent topics in Ignacio Melero's work include Immunotherapy and Immune Responses (180 papers), Cancer Immunotherapy and Biomarkers (153 papers) and CAR-T cell therapy research (132 papers). Ignacio Melero is often cited by papers focused on Immunotherapy and Immune Responses (180 papers), Cancer Immunotherapy and Biomarkers (153 papers) and CAR-T cell therapy research (132 papers). Ignacio Melero collaborates with scholars based in Spain, United States and United Kingdom. Ignacio Melero's co-authors include José Luis Perez‐Gracia, Bruno Sangro, Miguel F. Sanmamed, María E. Rodríguez-Ruiz, Sandra Hervás‐Stubbs, Jesús Prìeto, David Sancho, Lieping Chen, Francisco J. Cueto and Pedro Berraondo and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Ignacio Melero

384 papers receiving 27.8k citations

Hit Papers

Dendritic cells in ... 1997 2026 2006 2016 2019 2021 2018 2013 1997 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dendritic cells in cancer immunology and immunotherapy
    2019 1.8k citations Ignacio Melero, David Sancho et al. profile →
  2. Advances in immunotherapy for hepatocellular carcinoma
    2021 871 citations Bruno Sangro, Sandra Hervás‐Stubbs et al. profile →
  3. Cytokines in clinical cancer immunotherapy
    2018 855 citations Pedro Berraondo, Miguel F. Sanmamed et al. profile →
  4. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    2013 764 citations Bruno Sangro, Mercedes Iñarrairaegui et al. profile →
  5. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
    1997 727 citations Ignacio Melero, Lieping Chen et al. profile →
  6. Therapeutic vaccines for cancer: an overview of clinical trials
    2014 614 citations Ignacio Melero et al. profile →
  7. Cancer vaccines: the next immunotherapy frontier
    2022 553 citations Ignacio Melero et al. profile →
  8. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    2015 498 citations Ignacio Melero, M. Ángela Aznar et al. profile →
  9. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
    2019 470 citations Deborah B. Doroshow, Miguel F. Sanmamed et al. Clinical Cancer Research profile →
  10. Immunological landscape and immunotherapy of hepatocellular carcinoma
    2015 470 citations Ignacio Melero, Bruno Sangro et al. profile →
  11. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
    2019 449 citations Kurt A. Schalper, María E. Rodríguez-Ruiz et al. profile →
  12. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
    2018 356 citations María E. Rodríguez-Ruiz, Ignacio Melero et al. profile →
  13. Intratumoural administration and tumour tissue targeting of cancer immunotherapies
    2021 342 citations Ignacio Melero, Maite Álvarez et al. profile →
  14. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
    2020 333 citations Ignacio Melero et al. profile →
  15. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    2019 323 citations Luna Minute, Itziar Otano et al. profile →
  16. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
    2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →
  17. Paradigms on Immunotherapy Combinations with Chemotherapy
    2021 278 citations José Luis Perez‐Gracia, María E. Rodríguez-Ruiz et al. Cancer Discovery profile →
  18. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
    2020 274 citations Bruno Sangro, Ignacio Melero et al. profile →
  19. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
    2021 141 citations Ignacio Melero, Jaclyn Neely et al. profile →
  20. Cross-priming in cancer immunology and immunotherapy
    2025 33 citations Carlos Luri‐Rey, Álvaro Teijeira et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ignacio Melero Spain 88 16.8k 15.8k 6.6k 3.0k 2.4k 396 28.2k
Elizabeth M. Jaffee United States 89 15.8k 0.9× 18.4k 1.2× 9.3k 1.4× 3.9k 1.3× 4.0k 1.7× 386 30.7k
Weiping Zou United States 79 19.8k 1.2× 16.9k 1.1× 10.9k 1.6× 4.1k 1.3× 5.0k 2.1× 188 35.3k
Robert H. Vonderheide United States 74 14.2k 0.8× 15.2k 1.0× 6.9k 1.0× 2.4k 0.8× 3.2k 1.4× 224 25.0k
Padmanee Sharma United States 63 13.9k 0.8× 20.0k 1.3× 6.5k 1.0× 5.8k 1.9× 2.9k 1.2× 257 28.5k
Dario A.A. Vignali United States 85 22.9k 1.4× 12.2k 0.8× 7.0k 1.1× 1.6k 0.5× 2.4k 1.0× 242 33.4k
Atsushi Miyajima Japan 84 10.2k 0.6× 8.7k 0.6× 10.3k 1.6× 1.3k 0.4× 2.5k 1.0× 364 26.6k
Lieping Chen United States 112 36.0k 2.1× 34.3k 2.2× 9.2k 1.4× 6.6k 2.2× 3.4k 1.4× 368 55.6k
Kai W. Wucherpfennig United States 81 14.5k 0.9× 7.0k 0.4× 6.4k 1.0× 2.6k 0.8× 2.0k 0.9× 203 23.9k
Thomas F. Gajewski United States 82 20.9k 1.2× 19.8k 1.3× 11.9k 1.8× 3.1k 1.0× 2.5k 1.1× 321 36.1k
Ton N. Schumacher Netherlands 83 22.7k 1.3× 17.9k 1.1× 9.7k 1.5× 2.4k 0.8× 2.5k 1.0× 311 34.3k

Countries citing papers authored by Ignacio Melero

Since Specialization
Citations

This map shows the geographic impact of Ignacio Melero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Melero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Melero more than expected).

Fields of papers citing papers by Ignacio Melero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Melero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Melero. The network helps show where Ignacio Melero may publish in the future.

Co-authorship network of co-authors of Ignacio Melero

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Melero. A scholar is included among the top collaborators of Ignacio Melero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Melero. Ignacio Melero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Belsúe, Virginia, et al.. (2024). Tumor slice culture system for ex vivo immunotherapy studies. Methods in cell biology. 189. 55–69. 1 indexed citations
3.
Olivera, Irene, Elixabet Bolaños, Sandra Hervás‐Stubbs, et al.. (2023). mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Reports Medicine. 4(3). 100978–100978. 32 indexed citations
4.
Melero, Ignacio, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.. (2022). CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery. 13(3). 552–569. 51 indexed citations
5.
Vásquez, Marcos, Maite Álvarez, Itziar Otano, et al.. (2021). Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. Journal for ImmunoTherapy of Cancer. 9(7). e001587–e001587. 13 indexed citations
6.
Minute, Luna, Álvaro Teijeira, Alfonso R. Sánchez-Paulete, et al.. (2020). Cellular cytotoxicity is a form of immunogenic cell death. Journal for ImmunoTherapy of Cancer. 8(1). e000325–e000325. 71 indexed citations
7.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251. 6 indexed citations
8.
Doroshow, Deborah B., Miguel F. Sanmamed, Katherine Hastings, et al.. (2019). Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research. 25(15). 4592–4602. 470 indexed citations breakdown →
9.
Teijeira, Álvaro, Sara Labiano, Saray Garasa, et al.. (2018). Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation. Cancer Immunology Research. 6(7). 798–811. 65 indexed citations
10.
Iñarrairaegui, Mercedes, Ignacio Melero, & Bruno Sangro. (2017). Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clinical Cancer Research. 24(7). 1518–1524. 190 indexed citations
11.
Aznar, M. Ángela, Sara Labiano, Ángel Díaz‐Lagares, et al.. (2017). CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes. Cancer Immunology Research. 6(1). 69–78. 35 indexed citations
12.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →
13.
Rodríguez-Ruiz, María E., Inmaculada Rodríguez, Saray Garasa, et al.. (2016). Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research. 76(20). 5994–6005. 198 indexed citations
14.
Sanmamed, Miguel F., Inmaculada Rodríguez, Kurt A. Schalper, et al.. (2015). Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice. Cancer Research. 75(17). 3466–3478. 129 indexed citations
15.
Weigelin, Bettina, Elixabet Bolaños, Álvaro Teijeira, et al.. (2015). Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences. 112(24). 7551–7556. 81 indexed citations
16.
Quetglas, José I., Sara Labiano, M. Ángela Aznar, et al.. (2015). Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunology Research. 3(5). 449–454. 89 indexed citations
17.
Sanmamed, Miguel F., Carlos Alfaro, Carmen Oñate, et al.. (2014). Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research. 20(22). 5697–5707. 204 indexed citations
18.
Melero, Ignacio, José I. Quetglas, Juan Dubrot, et al.. (2014). Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12. Cancer Research. 75(3). 497–507. 35 indexed citations
19.
Morales‐Kastresana, Aizea, Miguel F. Sanmamed, Inmaculada Rodríguez, et al.. (2013). Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. Clinical Cancer Research. 19(22). 6151–6162. 81 indexed citations
20.
Berraondo, Pedro, Viktor Umansky, & Ignacio Melero. (2012). Changing the Tumor Microenvironment: New Strategies for Immunotherapy. Cancer Research. 72(20). 5159–5164. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth M. Jaffee Breakdown of academic impact, for papers by Weiping Zou Breakdown of academic impact, for papers by Robert H. Vonderheide Breakdown of academic impact, for papers by Padmanee Sharma Breakdown of academic impact, for papers by Dario A.A. Vignali Breakdown of academic impact, for papers by Atsushi Miyajima Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Kai W. Wucherpfennig Breakdown of academic impact, for papers by Thomas F. Gajewski Breakdown of academic impact, for papers by Ton N. Schumacher
Rankless by CCL
2026